One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

European Journal of Neurology

Volumn 16, Issue 11, 2009, Pages 1202-1209

  Prosperini, L ^a   Gallo, V ^a,b   Petsas, N ^c   Borriello, G ^a   Pozzilli, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Neurological Centre of Latium   (Italy)

Author keywords

Interferon beta; Magnetic resonance imaging; Multiple sclerosis; Response to therapy

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; DRUG FORMULATION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE OF ONSET; CHILD; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 70350135509     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02708.x     Document Type: Article

References (30)

1. The IFN beta Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFN Beta Multiple Sclerosis Study Group. Neurology 1993 43 : 655 661.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996 39 : 285 294.
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 352 : 1498 1504.
4. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFN Beta Multiple Sclerosis Study Group. Neurology 1993 43 : 662 667.
5. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative research Group. Ann Neurol 1998 43 : 79 87.
6. Li DK, Paty DW. Magnetic Resonance Imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis. Ann Neurol 1999 42 : 197 206.
7. Dubois BD, Keenan E, Porter BE, et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 2003 74 : 946 949.
8. Rio J, Tintoré M, Nos C, et al. Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre. J Neurol 2005 252 : 795 800.
9. O'Rourke K, Walsh C, Hutchinson M. Outcome of Beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol 2007 254 : 1547 1554. (Pubitemid 350159898)
10. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon beta-treated relapsing multiple sclerosis. Ann Neurol 2007 61 : 300 306.
11. Roullet E, Dominique P, Le Canuet P, et al. Application of different criteria for clinical response to beta-interferon in relapsing-remitting multiple sclerosis. Neurology 2003 60 (Suppl. 1 A168.
12. Rio J, Nos C, Tintoré M, et al. Defining the response to interferon beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006 59 : 344 352. (Pubitemid 43202488)
13. Kurtzke JF. Rating neurological impairment in multiple sclerosis. An expanded disability status scale (EDSS). Neurology 2003 33 : 1444 1452.
14. Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003 61 : 184 189.
15. Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006 253 : 287 293.
16. O'Rourke K, Walsh C, Antonelli G, et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007 13 : 336 342.
17. Miller DH, Grossman R, Reingold S, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998 121 : 3 24.
18. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines form the International Panel on the diagnosis of Multiple Sclerosis. Ann Neurol 2001 50 : 121 127.
19. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996 39 : 6 16.
20. Sormani MP, Bruzzi P, Beckmann K, et al. The distribution of magnetic resonance imaging response to interferon beta-1b in multiple sclerosis. J Neurol 2005 252 : 1455 1458. (Pubitemid 41803833)
21. Freedman MS, Patry DG, Grand'Maison F, et al. Canadian MS Working Group. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004 31 : 157 168.
22. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as surrogate outcome measure in multiple sclerosis. Mult Scler 2002 8 : 40 51.
23. Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004 56 : 548 555.
24. Rio J, Rovira A, Tintoré M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008 14 : 479 484.
25. Koudriavtseva T, Pozzilli C, Fiorelli M, et al. Determinants of Gd-enhanced MRI response to IFN beta-1a treatment in relapsing-remitting multiple sclerosis. Mult Scler 1998 4 : 403 407.
26. Durelli L, Berbero P, Bergui M, et al. MRI activity and neutralizing antibody as predictor of response to IFNB treatment in MS. J Neurol Neurosurg Psychiatry 2008 79 : 646 651.
27. Miller DH, Barkhof F, Frank JA, et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002 125 : 1676 1695.
28. Fisher E, Rudick RA, Simon JH, et al. Eight year follow-up study of brain atrophy in patients with MS. Neurology 2002 59 : 1412 1420.
29. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003 61 : 551 554.
30. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005 11 : 306 309.